ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Debut Biotech has raised $22.6 million in series A funding from several venture capital firms. The San Diego–based company says it will use the funds to commercialize ingredients made with its cell-free, enzyme-based production technology. Debut recently signed a deal with Japan’s DIC to use the technology to make natural color ingredients. It also has an ingredient-making deal with DSM.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter